Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MangoceuticalsMGRX +7.63%26 Debt-to-Equity is 0.03 as of Jun. 2026, which is 50% above its 10-year median of 0.02. GuruFocus rates MGRX with a GF Score™ of 26/100 and a GF Value™ of $0.19 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 560 Healthcare Providers & Services companies, Mangoceuticals ranks better than 90.71% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Mangoceuticals's Debt-to-Equity or its related term are showing as below:
MGRX'
s Debt-to-Equity Range Over the Past 10 Years
Min: -2.29 Med: 0.02 Max: 0.58
Current: 0.03
During the past 5 years, the highest Debt-to-Equity Ratio of Mangoceuticals was 0.58. The lowest was -2.29. And the median was 0.02.
MGRX's Debt-to-Equity is ranked better than 90.71% of 560
companies
in the Healthcare Providers & Services industry
Industry Median: 0.42
vs MGRX: 0.03
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Mangoceuticals Debt-to-Equity Related Terms
Mangoceuticals Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Mangoceuticals's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MGRX vs PBSV, VYND, BRGX: Debt-to-Equity Comparison
For the Health Information Services subindustry, Mangoceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mangoceuticals Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Mangoceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Mangoceuticals's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mangoceuticals (MGRX) has a Debt-to-Equity of 0.03 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Mangoceuticals and its competitors. This is 50% above median its historical median of 0.02. According to the industry distribution chart, Mangoceuticals ranks #52 out of 560 companies in the Healthcare Providers & Services industry, placing it in the top 9.3%.
Is Mangoceuticals' Debt-to-Equity too high?
Mangoceuticals' current Debt-to-Equity of 0.03 is 50% above median its 10-year median of 0.02. The Healthcare Providers & Services industry median Debt-to-Equity is 0.42. Mangoceuticals' value of 0.03 is 92.9% below this industry median. Based on the distribution chart, Mangoceuticals ranks #52 out of 560 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Mangoceuticals has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mangoceuticals' Debt-to-Equity compare to PBSV and VYND?
According to the Healthcare Providers & Services industry distribution chart, Mangoceuticals ranks #52 out of 560 companies for Debt-to-Equity. This places Mangoceuticals in the top 9% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.42. Mangoceuticals' value of 0.03 is 92.9% below this benchmark. While the company's 10-year median is 0.02 vs. the industry median of 0.42, Mangoceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.42, based on 560 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mangoceuticals's current Debt-to-Equity of 0.03 is 92.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Mangoceuticals and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mangoceuticals's current Debt-to-Equity is 0.03, which is 50% above median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mangoceuticals stock overvalued right now?
Based on GuruFocus' analysis, Mangoceuticals (MGRX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.19, compared to a current price of $0.42 — trading 118.9% above its estimated fair value. The current Debt-to-Equity is 0.03, which is 50% above median its 10-year median of 0.02 and 92.9% below the Healthcare Providers & Services industry median of 0.42. Mangoceuticals' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Mangoceuticals (MGRX), the current Debt-to-Equity is 0.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mangoceuticals (MGRX) Overvalued in 2026?
Based on GuruFocus' analysis, Mangoceuticals stock appears to be overvalued.
The current stock price of $0.42 is trading 118.9% above its estimated GF Value™ of $0.19.
GuruFocus considers Mangoceuticals to be Significantly Overvalued.
Key valuation signals for MGRX:
Debt-to-Equity: 0.03 (50% above median its 10-year median of 0.02)
GF Value™: $0.19 vs. price of $0.42 (118.9% above fair value)
Industry Position: 92.9% below the Healthcare Providers & Services median (#52 of 560)
No single metric tells the full story. See the MGRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
26GF Score
Get the complete analysis for MGRX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MGRX has been successfully added to your 
